A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)
Clinical trial NCT02256436 · COMPLETED
Trial details
- NCT number
- NCT02256436
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2014-10-22
- Primary completion
- 2016-09-07
- Enrollment
- 542
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.